Tourmaline Bio Inc (TRML)

18.25 -0.68 (-3.59%)
Closed USD Disclaimer
19.16 +0.91 (+4.99%)

Tourmaline Bio Inc Company Profile

Equity Type
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Contact Information
New York,10010 United States
Top Executives
Caley M. Castelein 52 0000 Director
Sandeep C. Kulkarni 41 0000 Co-Founder, CEO & Director
Parvinder Singh Thiara 0 0000 Director
Sapna Srivastava 52 0000 Director
Aaron Kantoff 38 0000 Director
Mark D. McDade 68 0000 Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.